SI-BONE INC (SIBN) Stock Fundamental Analysis
USA - NASDAQ:SIBN - US8257041090 - Common Stock
15 USD
+0.17 (+1.15%)
SIBN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. SIBN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SIBN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SIBN had negative earnings in the past year.
SIBN had a negative operating cash flow in the past year.
In the past 5 years SIBN always reported negative net income.
In the past 5 years SIBN always reported negative operating cash flow.
1.2 Ratios
SIBN has a Return On Assets of -10.29%. This is in the better half of the industry: SIBN outperforms 60.32% of its industry peers.
With a decent Return On Equity value of -13.95%, SIBN is doing good in the industry, outperforming 62.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.29% | ||
| ROE | -13.95% | ||
| ROIC | N/A |
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SIBN has a better Gross Margin (79.45%) than 92.06% of its industry peers.
SIBN's Gross Margin has declined in the last couple of years.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SIBN has more shares outstanding
Compared to 5 years ago, SIBN has more shares outstanding
SIBN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.00 indicates that SIBN is not in any danger for bankruptcy at the moment.
SIBN has a better Altman-Z score (5.00) than 78.84% of its industry peers.
SIBN has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SIBN has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5 |
ROIC/WACCN/A
WACC8.68%
2.3 Liquidity
A Current Ratio of 8.38 indicates that SIBN has no problem at all paying its short term obligations.
SIBN has a Current ratio of 8.38. This is amongst the best in the industry. SIBN outperforms 89.42% of its industry peers.
SIBN has a Quick Ratio of 7.00. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
SIBN's Quick ratio of 7.00 is amongst the best of the industry. SIBN outperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.38 | ||
| Quick Ratio | 7 |
3. Growth
3.1 Past
SIBN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.55%, which is quite impressive.
The Revenue has grown by 22.93% in the past year. This is a very strong growth!
Measured over the past years, SIBN shows a quite strong growth in Revenue. The Revenue has been growing by 19.96% on average per year.
EPS 1Y (TTM)44.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)22.93%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%21.67%
3.2 Future
SIBN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.39% yearly.
The Revenue is expected to grow by 16.49% on average over the next years. This is quite good.
EPS Next Y20%
EPS Next 2Y16.01%
EPS Next 3Y14.39%
EPS Next 5YN/A
Revenue Next Year18.28%
Revenue Next 2Y17.27%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SIBN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIBN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SIBN's earnings are expected to grow with 14.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.01%
EPS Next 3Y14.39%
5. Dividend
5.1 Amount
No dividends for SIBN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SIBN (11/3/2025, 1:52:03 PM)
15
+0.17 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners91.29%
Inst Owner Change-0.74%
Ins Owners3.01%
Ins Owner Change-2.02%
Market Cap647.10M
Revenue(TTM)185.26M
Net Income(TTM)-23764000
Analysts84
Price Target25.27 (68.47%)
Short Float %6.76%
Short Ratio6.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.12%
Min EPS beat(2)25.4%
Max EPS beat(2)34.83%
EPS beat(4)4
Avg EPS beat(4)30.16%
Min EPS beat(4)25.4%
Max EPS beat(4)34.83%
EPS beat(8)8
Avg EPS beat(8)23.87%
EPS beat(12)12
Avg EPS beat(12)23.06%
EPS beat(16)12
Avg EPS beat(16)14.23%
Revenue beat(2)1
Avg Revenue beat(2)0.86%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)2.63%
Revenue beat(4)2
Avg Revenue beat(4)-0.07%
Min Revenue beat(4)-2.34%
Max Revenue beat(4)2.63%
Revenue beat(8)6
Avg Revenue beat(8)1%
Revenue beat(12)9
Avg Revenue beat(12)1.73%
Revenue beat(16)11
Avg Revenue beat(16)1.14%
PT rev (1m)-0.89%
PT rev (3m)0.45%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)3.02%
EPS NY rev (1m)0%
EPS NY rev (3m)5.86%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.8 | ||
| P/tB | 3.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.29
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.29% | ||
| ROE | -13.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.45% | ||
| FCFM | N/A |
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 191.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.38 | ||
| Quick Ratio | 7 | ||
| Altman-Z | 5 |
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)219.68%
Cap/Depr(5y)238.27%
Cap/Sales(3y)6.94%
Cap/Sales(5y)6.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y20%
EPS Next 2Y16.01%
EPS Next 3Y14.39%
EPS Next 5YN/A
Revenue 1Y (TTM)22.93%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%21.67%
Revenue Next Year18.28%
Revenue Next 2Y17.27%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
EBIT growth 1Y39.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.65%
EBIT Next 3Y36.68%
EBIT Next 5YN/A
FCF growth 1Y66.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.22%
OCF growth 3YN/A
OCF growth 5YN/A
SI-BONE INC / SIBN FAQ
What is the ChartMill fundamental rating of SI-BONE INC (SIBN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SIBN.
What is the valuation status of SI-BONE INC (SIBN) stock?
ChartMill assigns a valuation rating of 0 / 10 to SI-BONE INC (SIBN). This can be considered as Overvalued.
How profitable is SI-BONE INC (SIBN) stock?
SI-BONE INC (SIBN) has a profitability rating of 2 / 10.
What is the expected EPS growth for SI-BONE INC (SIBN) stock?
The Earnings per Share (EPS) of SI-BONE INC (SIBN) is expected to grow by 20% in the next year.